(Q34560660)

3 August 2017

1 reference

title

The development of immunotherapies for non-small cell lung cancer (English)

1 reference

3 August 2017

1 reference

1 reference

Michael L Salgaller

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Expert Opinion on Biological Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

265-278

1 reference

3 August 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Immunological aspects of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumor Vaccine Design: Concepts, Mechanisms, and Efficacy Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumor immunology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumor escape from immune response by variation in HLA expression and other mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Surgery for stage IIIa-N2 non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Human antibodies from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Imaging lung cancer with radiolabeled antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumor Heterogeneity and Immunotherapy of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

MHC antigens and tumor escape from immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells as vectors for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Regulation of T cell immunity by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Tumour surveillance: missing peptides and MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells presenting tumor antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Prostate cancer immunotherapy at the dawn of the new millennium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells for specific cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells: On the move from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Carcinoembryonic antigen as a target for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Paracrine cytokine adjuvants in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

The human hematopoietic colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

The granulocyte-macrophage colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Cytokine-secreting tumor cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.265

21 January 2018

Identifiers

DOI

10.1517/14712598.2.3.265

1 reference

3 August 2017

1 reference